These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 38580870)

  • 21. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Dysthe M; Parihar R
    Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives.
    Mortezaee K
    Life Sci; 2021 Jul; 277():119627. PubMed ID: 34004256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloid suppressor cells in cancer and autoimmunity.
    Sica A; Massarotti M
    J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developmental pathways of myeloid-derived suppressor cells in neoplasia.
    Abrams SI
    Cell Immunol; 2021 Feb; 360():104261. PubMed ID: 33373817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDSCs in bone metastasis: Mechanisms and therapeutic potential.
    Li Z; Xia Q; He Y; Li L; Yin P
    Cancer Lett; 2024 Jun; 592():216906. PubMed ID: 38649108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.
    Albini A; Bruno A; Noonan DM; Mortara L
    Front Immunol; 2018; 9():527. PubMed ID: 29675018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roles of Myeloid-Derived Suppressor Cells in Cancer Metastasis: Immunosuppression and Beyond.
    Pastaki Khoshbin A; Eskian M; Keshavarz-Fathi M; Rezaei N
    Arch Immunol Ther Exp (Warsz); 2019 Apr; 67(2):89-102. PubMed ID: 30386868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
    Hou A; Hou K; Huang Q; Lei Y; Chen W
    Front Immunol; 2020; 11():783. PubMed ID: 32508809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
    Huo S; Liu L; Li Q; Wang J
    Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.
    Chesney JA; Mitchell RA; Yaddanapudi K
    J Leukoc Biol; 2017 Sep; 102(3):727-740. PubMed ID: 28546500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.
    Tuettenberg A; Steinbrink K; Schuppan D
    Nanomedicine (Lond); 2016 Oct; 11(20):2735-2751. PubMed ID: 27658725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy.
    Zhao J; Dong Y; Zhang Y; Wang J; Wang Z
    Adv Drug Deliv Rev; 2022 Dec; 191():114585. PubMed ID: 36273512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
    Cresswell GM; Wang B; Kischuk EM; Broman MM; Alfar RA; Vickman RE; Dimitrov DS; Kularatne SA; Sundaram CP; Singhal S; Eruslanov EB; Crist SA; Elzey BD; Ratliff TL; Low PS
    Cancer Res; 2021 Feb; 81(3):671-684. PubMed ID: 33203700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature.
    Xu H; Russell SN; Steiner K; O'Neill E; Jones KI
    Cancer Immunol Immunother; 2024 Aug; 73(10):204. PubMed ID: 39105848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-associated myeloid cells as guiding forces of cancer cell stemness.
    Sica A; Porta C; Amadori A; Pastò A
    Cancer Immunol Immunother; 2017 Aug; 66(8):1025-1036. PubMed ID: 28401258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer-cell-intrinsic mechanisms regulate MDSCs through cytokine networks.
    Zhang Y; Murphy S; Lu X
    Int Rev Cell Mol Biol; 2023; 375():1-31. PubMed ID: 36967150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity.
    Kramer ED; Abrams SI
    Front Immunol; 2020; 11():1963. PubMed ID: 32983128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor.
    Yan D; Adeshakin AO; Xu M; Afolabi LO; Zhang G; Chen YH; Wan X
    Front Immunol; 2019; 10():1399. PubMed ID: 31275326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics.
    Adah D; Hussain M; Qin L; Qin L; Zhang J; Chen X
    Pharmacol Res; 2016 Aug; 110():25-34. PubMed ID: 27157248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
    Carnevalli LS; Ghadially H; Barry ST
    Front Immunol; 2021; 12():633685. PubMed ID: 33953710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.